Related Experiment Video

Updated: Apr 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Angiotensin type 1 receptor A1166C gene polymorphism is associated with endothelial dysfunction and in-stent

Yu Li1, Fang Chen1, Xiaoling Zhang1

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University Chaoyang District 100029, Beijing, China.

International Journal of Clinical and Experimental Pathology
|August 12, 2015
PubMed

Insights

The angiotensin type 1 receptor (AT1R) CC genotype is linked to endothelial dysfunction and in-stent restenosis (ISR) after percutaneous coronary intervention (PCI). This finding supports genome-based cardiovascular disease prevention strategies.

Area of Science:

  • Cardiovascular Genetics
  • Interventional Cardiology
  • Endothelial Biology

Background:

  • Percutaneous coronary intervention (PCI) is vital for ischemic cardiovascular diseases but limited by in-stent restenosis (ISR).
  • Current preventive medications like aspirin and statins have adverse effects and limited efficacy in reducing ISR.
  • Altered endothelial function is a key factor contributing to post-PCI ISR.

Purpose of the Study:

  • To investigate the association between angiotensin type 1 receptor (AT1R) A1166C gene polymorphisms and endothelial dysfunction.
  • To determine the role of AT1R gene polymorphisms in the development of ISR following PCI.

Main Methods:

  • Prospective genotyping of 483 ST-elevation myocardial infarction (STEMI) patients undergoing PCI using PCR and RFLP.
  • Assessment of endothelial function via flow-mediated dilation (FMD) in relation to different AT1R genotypes.
  • Statistical analysis using univariable and multivariable models to evaluate the significance of AT1R polymorphisms in ISR development.

Main Results:

  • AT1R genotype distribution (AA, AC, CC) correlated with blood oxidative stress biomarkers and reduced FMD post-PCI (P<0.05).
  • The AT1R CC genotype showed a strong association with the development of ISR within 3 years post-PCI (OR=3.736, P<0.001).

Conclusions:

  • The CC genotype of the AT1R gene is linked to impaired endothelial function and increased risk of ISR after PCI.
  • These findings provide a basis for genome-based prevention strategies for cardiovascular diseases and pre-treatment considerations for patients undergoing PCI.
Abstract

Keywords:
Angiotensin type 1 receptorin-stent restenosispercutaneous coronary interventionpolymorphism

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.9K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86